Abstract The BCR/ABL gene rearrangement is cytogenetically visualized in most chronic myeloid leukemia (CML) cases. About 5-10 % of CML patients lack its cytogenetic evidence, however, shows BCR/ABL fusion by molecular methods. We describe two CML patients with Philadelphia (Ph) negative (-ve) and BCR/ABL positive by fluorescence in situ hybridization (FISH). Both the cases were in chronic phase at diagnosis. Conventional cytogenetics and different FISH assays were adopted using BCR/ ABL probes. Home-brew FISH assay using bacterial artificial clone (BAC) for BAC-CTA/bk 299D3 for chromosomal region 22q13.31-q13.32 was performed in case 1. Both the patients were Ph-ve. In first case, dual color dual fusion (DCDF)-FISH studies revealed 1 Red (R) 2 Green (G) 1 Fusion (F) signal pattern in 80 % of cells indicating BCR/ABL fusion signals on chromosomes 9 instead of Ph and 2G2F signal pattern in 20 % of cells indicating two BCR/ABL fusions on both chromosomes 9q34 on presentation. In second case, FISH studies revealed the 1R1G1F signal pattern indicating BCR/ABL fusion signals on chromosomes 9 instead of Ph in 100 % of cells at presentation. During follow-up, both the patients exhibited 2G2F signal pattern indicating two BCR/ABL fusions on both chromosomes 9q34, which indicated a clonal evolution in 100 % cells. Both the patients did not achieve therapeutic response. Relocation of BCR/ABL fusion sequence on sites other than 22q11 represents a rare type of variant Ph, the present study highlights the hot spots involved in CML pathogenesis and signifies their implications in Ph-ve BCR/ABL positive CML. This study demonstrated the genetic heterogeneity of this subgroup of CML and strongly emphasized the role of metaphase FISH, especially in Ph-ve CML cases, as it detects variations of the classical t(9;22).
Introduction
The presence of Philadelphia (Ph) chromosome is characteristic chromosomal marker for more than 90 % of chronic myeloid leukemia (CML) cases. Cytogenetically, Ph chromosome is the result of the reciprocal translocation between chromosome 9 and 22 with 9q34 and 22q11 breakpoints. On molecular level, two hybrid genes are formed by this translocation: BCR/ABL, which is in the vast majority of the cases localized on the Ph chromosome. Most patients have breakpoints that result in a fusion mRNA in which either BCR exon b2 or b3 is joined to ABL exon a2. It is generally accepted that inception of BCR/ABL hybrid gene and its product plays one of the main role in pathogenesis of CML [1] . It is reported that around 2-4 % of patients with typical clinical features of CML do not posses Ph chromosome in bone marrow cells, however, are positive for BCR/ABL when analyzed by Southern blotting or reverse transcriptase-polymerase chain reaction (RT-PCR) [2] . Mostly, the rearranged gene localized on band 22q11 in these cases by in situ hybridization. Several investigators have reported localization of the fusion gene in region 9q34 [3] [4] [5] [6] [7] , thereby indicating that it is not such a rare event [8] . Different mechanisms of origin of this rearrangement have been suggested. According to Hagemeijer et al. [3] it could be the result of a one step insertion. Viera et al. [9] hypothesized two translocations. Tanaka et al. [10] suggested segmental translocation which he defined as transposition.
To the best of our knowledge, only six cases with BCR/ ABL positive CML with localization of fused gene on both the homologues of chromosome 9 in region 9q34 are reported among which the last case was reported in 2005 [11, 12] . Here, we report two more patients with Ph-ve, BCR/ABL positive CML with localization of fused gene on both the homologues of chromosome 9 in region 9q34 with the results of conventional cytogenetics and fluorescence in situ hybridization (FISH). We found these two cases out of 361 de novo CML cases studied. The presence of two copies of BCR/ABL fusion gene could be the sign of start of acceleration and/or blast crisis of CML. However, according to clinical findings, both patients were in chronic phase of CML at the first hematologic examination.
Materials and Methods
The study was approved by institutional ethics committee and scientific review committee. 
Conventional Cytogenetics
Short-term culture of bone marrow cells harvesting and GTG banding was performed according to standard procedures following karyotyping according to ISCN 2009 guidelines [13, 14] . FISH Different FISH strategies were adopted; locus specific identifier (LSI) probes for BCR/ABL gene rearrangement, dual color dual fusion (DCDF), BCR/ABL-ES (extra signal) were performed in both the patients (Abbott MolecularVysis, Des Plaines, IL, USA) according to manufacturer's protocol. In case 1, BCR/ABL ? 9q34 Tricolor, Dual Fusion Translocation Probe (Abbott Molecular-Vysis, Des Plaines, IL, USA) was also performed.
Home-Brew FISH Probe
Bacterial artificial chromosomes (BACs) (a kind gift from Sanger center, Wellcome trust, UK) CTA/bk299D3 on 22q13.31-q13.32 tagged with spectrum green was used to know the mechanism behind localization of BCR/ABL fusion on 9q34 in case 1. Plasmid DNA was isolated by using Qiagen mini prep kit (USA). Nick translation and probe precipitation were done according to manufacturer's instructions for labeling of BAC DNA (Abbott MolecularVysis, Des Plaines, IL, USA).
Results

Conventional Cytogenetics
The first cytogenetic examination revealed normal karyotype 46,XY in all metaphases in both the patients. At different time intervals, the follow-up cytogenetic examination was carried out in both the patients. In patient 1, cytogenetic studies were carried for five times, the karyotype description are as follows; in February 2005, the karyotype was 46,XY [14] [9] and in July 200946,XY [10] , respectively. In both the patients the karyotype results were normal every time (Table 1) .
FISH
BCR/ABL-DCDF
The details of DCDF-FISH results at diagnosis and on follow-up are described in Table 1 for both patients (Figs. 1a, b, 2a1, a2) . Other BCR/ABL FISH strategies
In both the patients FISH with BCR/ABL-ES also showed unusual signal pattern 1R1G1F and 1G2F in both interphase and metaphase. The signal pattern 1R1G1F indicated, 1R on normal 9, 1 G on chromosome 22 and fusion on der(9) (Fig:  1c) . The signal pattern 1G2F indicated, 1 G on chromosome 22 and 2 fusion on both the chromosome 9 [ Fig: 1d] . FISH with BCR/ABL-Tri color showed no deletion of ABL/ASS observed [ Fig. 1e-f] . The patient1 was having BCR/ABL fusion on both the 9 chromosome instead of Ph. BAC-FISH was carried out using CTA/bk299D3 situated on terminal region of q arm of chromosome 22, below the BCR gene. It was tagged with green spectrum. Both of the green signals for BAC-CTA/bk299D3 were present on 22q13.32. It indicated that, only part of BCR gene was inserted into 9q34, whereas rest of the part was remained on der(22), hence provided a clue for insertion mechanism (Fig. 3a, b) .
Discussion
Cryptic BCR/ABL rearrangements can be found in cases with a normal karyotype [15] and in cases with complex karyotype in which the t(9;22) is not detected by conventional cytogenetic analysis. Incidence of such normal cases is reported to be around 1 % cases. These rearrangements can be revealed by FISH [16] . Complex rearrangements in some cases represent secondary changes arising likely from two consecutive translocations with a total of four breaks, or may arise from multiple simultaneous breaks in some patients. The first translocation results in t(9;22)(q34;q11). The second translocation occurs involving a break distal at band 9q34 and another break on a third chromosome [17] .
The most frequent location of the BCR/ABL fusion gene in complex chromosomal rearrangement is 22q11.2 [7] , but in rare variant cases BCR/ABL is translocated on other sites. At least 25 cases [18] described in the literature showed fusion gene located at 9q34. Despite the advances made in defining translocations related oncogenes in CML, the molecular mechanisms of leukemogenesis in the Ph-ve BCR/ABL positive CML cases remain to be defined.
Of special interest, the patients in present study had two BCR/ABL fusion gene in each cell located at 9q34. Six similar Ph-ve cases with double BCR/ABL fusion genes have been published previously [12] ; four were in chronic phase, two were in myeloid blast crisis. In agreement with hypothesis of Hagemeijer et al. [3] , we presume that the first molecular and cytogenetic event in bone marrow cells of both patients could be the insertion of the 5 0 part of the BCR gene within or at the 5 0 side of the ABL gene on chromosome 9. The second event was duplication of the rearranged chromosome 9 together with the loss of normal chromosome 9.
Previously reported cases with two Ph chromosomes or double BCR/ABL fusion signals have been found in the bone marrow cells of the patients in transformation to accelerate and/or in blast crisis of CML. During the transformation the additional chromosomal abnormalities to Ph chromosome could be seen in some patients and are considered as indicating unfavorable prognosis. The same applies for patients with BCR/ABL fusion gene on 9q34 [2] . Clinically, both the patients in present investing were in chronic phase at the time of diagnosis. Essential results were obtained by FISH with specific LSI BCR/ABL probe, which determined the location of fused gene on both chromosomes no. 9 and gave warning of poor prognosis of the patients. It was repeatedly hypothesized, based on the course of the disease of previously published cases that prognosis of patients with two Ph chromosomes and/or BCR/ABL gene located on one or both chromosome 9 is generally very poor [11] . Out of six cases reported in the literature, only one received imatinib treatment and achieved complete response [12] . Both the patients received imatinib treatment; it may be stated that the therapy with Glivec proved to be efficient from clinical point of view. The unusual location of BCR/ABL sequences on a chromosome 9 and the duplication of this chromosome apparently did not confer hematologic response. However for cytogenetic response, it needs further followup studies.
The current investigation documented that patient with normal karyotype showed BCR/ABL rearrangement. These patients may have atypical signal pattern of BCR/ABL rearrangement. In addition, we have prioritized observations from metaphase chromosomes, whereas most studies depended on interphase FISH analysis. Such analysis improves the knowledge of the genesis and the outcomes of CML, which remains a more heterogeneous disease than previously believed.
